The 5 Best Peptides for Muscle Growth in 2026

1. Ipamorelin + CJC-1295 (DAC) — The Gold Standard GH Stack

If you’re looking at peptides for muscle growth, this combination is where most researchers start — and for good reason. Ipamorelin is a selective growth hormone secretagogue that stimulates pulsatile GH release from the pituitary without significantly raising cortisol or prolactin. CJC-1295 with Drug Affinity Complex (DAC) is a growth hormone-releasing hormone (GHRH) analog with an extended half-life of approximately 6-8 days, providing sustained elevation of baseline GH levels.

Together, they produce a synergistic effect: CJC-1295 raises the baseline, and Ipamorelin amplifies the pulsatile peaks. The result is a GH secretion pattern that more closely mimics the high-amplitude pulses seen in young, healthy adults — the kind of GH profile associated with lean mass accrual, fat oxidation, and connective tissue repair.

The Evidence

A Phase 2 clinical trial of CJC-1295 (Teichman et al., 2006, Journal of Clinical Endocrinology & Metabolism) demonstrated that a single 30 mcg/kg dose elevated mean GH levels by 2-10 fold for 6+ days and increased IGF-1 levels by 1.5-3 fold for 9-11 days. These elevations are within the physiological range that supports anabolism without the supraphysiological spikes associated with exogenous GH injection.

Ipamorelin has been studied in multiple clinical contexts and consistently shows dose-dependent GH release with minimal side effects. A study by Raun et al. (1998, European Journal of Endocrinology) confirmed its selectivity — unlike older GH secretagogues like GHRP-6, ipamorelin does not significantly stimulate ACTH, cortisol, or prolactin release at therapeutic doses.

Practical Considerations

• Typical research protocol: Ipamorelin 200-300 mcg + CJC-1295 (no DAC) 100 mcg, 2-3x daily subcutaneously. CJC-1295 with DAC is dosed 2 mg once or twice weekly.
• Expected timeline: Measurable changes in body composition at 8-12 weeks. Strength and recovery improvements often reported earlier (4-6 weeks).
• Magnitude of effect: Don’t expect steroid-level gains. The effect is more analogous to optimizing GH levels in a 25-year-old — meaningful for body composition, substantial for recovery, but not transformative in isolation.
• Best for: Researchers over 30 whose endogenous GH production has declined. Also valuable for recovery from training-induced muscle damage and connective tissue support.

2. IGF-1 LR3 — Direct Growth Factor Signaling

IGF-1 LR3 (Insulin-like Growth Factor-1 Long Arg3) is a modified version of IGF-1 with a significantly longer half-life (~20-30 hours vs 12-15 minutes for native IGF-1). Unlike GH secretagogues that work upstream by increasing GH output, IGF-1 LR3 acts directly on the IGF-1 receptor, bypassing the GH→liver→IGF-1 axis entirely.

IGF-1 is arguably the most potent endogenous anabolic signal for skeletal muscle. It stimulates satellite cell proliferation (muscle stem cell activation), promotes myogenic differentiation, enhances protein synthesis via the PI3K/Akt/mTOR pathway, and has anti-apoptotic effects on muscle fibers. The LR3 variant has reduced binding to IGF-binding proteins, meaning more free IGF-1 is available to activate receptors.

The Evidence

The evidence for IGF-1’s anabolic effects is extensive in animal models and mechanistic cell studies. Barton-Davis et al. (1998, PNAS) demonstrated that viral-mediated IGF-1 overexpression in mouse muscle produced a 15% increase in muscle mass and a 14% increase in strength — and the effect was even more pronounced in aged mice (27% strength increase). In human studies, recombinant IGF-1 (mecasermin/Increlex) has been used clinically for growth failure and shows clear anabolic effects.

However, direct human studies on IGF-1 LR3 specifically for hypertrophy in healthy adults are limited, and most evidence is extrapolated from the broader IGF-1 literature and animal models.

Practical Considerations

• Typical research protocol: 20-50 mcg/day subcutaneously or intramuscularly, cycled 4-6 weeks on / 2-4 weeks off
• Hypoglycemia risk: IGF-1 LR3 lowers blood glucose significantly. Researchers must monitor glucose levels carefully, especially when combining with other insulin-sensitizing agents.
• Magnitude of effect: More potent than GH secretagogues for direct muscle tissue effects, but carries more risk and requires more careful dosing.
• Best for: Advanced researchers who have already optimized GH secretagogue protocols and want to explore direct growth factor signaling.

3. BPC-157 — The Recovery Accelerator

BPC-157 (Body Protection Compound-157) is a 15-amino acid peptide derived from human gastric juice. It doesn’t directly stimulate muscle hypertrophy in the way IGF-1 or GH do. Instead, BPC-157’s value for muscle growth is indirect: it dramatically accelerates recovery from training-induced damage, tendon and ligament injuries, and inflammation — allowing higher training frequency and volume, which are the primary drivers of long-term hypertrophy.

The Evidence

BPC-157 has been studied extensively in animal models for tissue repair. Staresinic et al. (2006) demonstrated accelerated healing of transected quadriceps muscle in rats. Pevec et al. (2010) showed accelerated Achilles tendon healing. The proposed mechanisms include upregulation of growth hormone receptor expression in injured tissues, promotion of angiogenesis (new blood vessel formation via VEGF pathway), and modulation of the nitric oxide system.

A key study by Chang et al. (2011) showed that BPC-157 promoted tendon-to-bone healing by stimulating growth factor expression including EGF, VEGF, and TGF-beta. While human clinical trial data remains limited (several trials are ongoing as of 2026), the breadth and consistency of animal data is compelling.

Practical Considerations

• Typical research protocol: 250-500 mcg/day subcutaneously, either systemically or locally near the site of injury. Can be run continuously for 4-8 weeks.
• Magnitude of effect: Not a muscle builder per se — it’s a recovery compound. But for anyone whose training is limited by tendon pain, joint inflammation, or slow recovery between sessions, BPC-157 can be transformative.
• Oral bioavailability: Unlike most peptides, BPC-157 shows evidence of oral bioavailability, which is consistent with its origin as a gastric peptide. Some researchers use oral administration for systemic effects.
• Best for: Researchers dealing with nagging injuries, tendon issues, or anyone who trains at high volume and needs faster recovery.

4. Tesamorelin — FDA-Approved GH Releasing

Tesamorelin (brand name Egrifta) is a synthetic analog of growth hormone-releasing hormone (GHRH) and is FDA-approved for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. This makes it one of the few peptides in this list with robust human clinical data from randomized controlled trials.

The Evidence

The Phase 3 trials for tesamorelin (Falutz et al., 2007, 2010) demonstrated significant reductions in visceral adipose tissue (VAT) — approximately 15-18% reduction at 26 weeks — along with meaningful increases in IGF-1 levels (approximately 80-100% increase from baseline). While the primary endpoint was fat reduction, secondary analyses showed modest improvements in lean body mass in some patient subgroups.

Importantly, tesamorelin stimulates GH release through the natural GHRH pathway, maintaining pulsatile secretion patterns and negative feedback loops — unlike exogenous GH, which suppresses endogenous production. This makes it a more physiological approach to GH optimization.

Practical Considerations

• FDA-approved dose: 2 mg subcutaneously once daily
• Magnitude of effect: Strong for fat reduction and GH/IGF-1 elevation. Modest direct effect on lean mass. Best viewed as a body composition optimizer rather than a pure muscle builder.
• Advantages: Best clinical evidence of any GHRH analog. Maintains natural GH pulsatility. FDA-approved (though for a specific indication).
• Best for: Researchers interested in simultaneous fat loss and lean mass preservation, particularly in the context of aging or metabolic dysfunction.

5. MK-677 (Ibutamoren) — The Oral GH Secretagogue

Technically, MK-677 is not a peptide — it’s a non-peptide ghrelin receptor agonist (growth hormone secretagogue). But it’s universally discussed in the peptide community and serves the same functional role: elevating GH and IGF-1 levels. Its key advantage is oral bioavailability — no injections required.

The Evidence

MK-677 has solid clinical data. Nass et al. (2008, Annals of Internal Medicine) studied MK-677 in healthy older adults over 2 years. Key findings: IGF-1 levels increased to those of young adults, GH pulsatility was restored, and lean body mass increased by approximately 1.1 kg at year 1 (though this didn’t reach statistical significance in the intent-to-treat analysis). Fat mass did not significantly change.

Murphy et al. (2001) demonstrated that 25 mg daily of MK-677 increased GH secretion by 97% in young healthy adults and by 78% in older adults over 14 days. IGF-1 increased by approximately 40-50% in both groups.

Practical Considerations

• Typical research protocol: 10-25 mg orally once daily, usually before bed (GH release is greatest during sleep)
• Duration: Can be run long-term (studies up to 2 years). Unlike GHRP peptides, MK-677 does not seem to lose efficacy over time due to receptor desensitization.
• Side effects: Significant appetite increase (ghrelin mimetic), water retention, potential insulin resistance with chronic use. Blood glucose monitoring is essential.
• Magnitude of effect: Comparable GH/IGF-1 elevation to injectable secretagogues, with the convenience of oral dosing. The trade-off is increased appetite and potential metabolic side effects.
• Best for: Researchers who want GH optimization without daily injections and are willing to manage appetite and monitor glucose levels.

What About Other Contenders?

A few compounds that didn’t make the top 5 but deserve mention:

• Follistatin 344 — myostatin inhibitor with dramatic effects in animal models, but limited human data and very short half-life make practical use challenging.
• TB-500 (Thymosin Beta-4) — strong recovery peptide often stacked with BPC-157, but evidence for direct hypertrophy effects is weaker.
• GHK-Cu — copper peptide with tissue remodeling properties, but its effects on skeletal muscle specifically are not well-characterized.
• GHRP-2 / GHRP-6 — older GH secretagogues that work but with more side effects (cortisol elevation, intense hunger with GHRP-6) than Ipamorelin. Largely superseded.

The Bottom Line

No peptide will replace progressive overload, adequate protein intake (1.6-2.2 g/kg/day), and sufficient sleep. Those fundamentals account for 90%+ of muscle growth outcomes. Peptides operate on the margins — optimizing hormonal signaling, accelerating recovery, and potentially extending the ceiling of what’s achievable naturally.

For most researchers, the Ipamorelin + CJC-1295 combination offers the best risk-to-reward ratio. For those dealing with injuries limiting training, BPC-157 is the priority. For researchers wanting the most potent direct anabolic signal, IGF-1 LR3 is the tool — with the caveat that it demands more careful management.

This article is for educational and research purposes only. These compounds are intended for use in controlled research settings. Always comply with local regulations.